PRECISE and Temus establish Joint Innovation Centre to advance precision health in Singapore. October 02, 2026 - 13:00 Five-year collaboration will build the technology, data, and delivery capabilities needed to translate genomic research into real-world healthcare applications under Singapore's National Precision Medicine programme. SINGAPORE - Media OutReach Newswire - 2 October 2026 - Precision Health Research, Singapore (PRECISE), and AI & digital transformation company, Temus, signed a memorandum of understanding to establish a PRECISE-Temus Joint Innovation Centre (JIC), a five-year collaboration to support the technology, data, and delivery capabilities for Phase III of Singapore's National Precision Medicine (NPM) programme. The signing took place at the Precision Health Partnerships in Singapore event, witnessed by Guest of Honour Mr Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies. The JIC brings together PRECISE's leadership of Singapore's national precision medicine programme with Temus's vision-to-value with velocity approach to transformation. It will help translate precision medicine from research into practical applications by strengthening the digital infrastructure, operating models, and safeguards needed to manage genomic data securely and responsibly. Supporting Phase III of NPM NPM's Phase III, launched in November 2025, aims to sequence the genomes of about 10 per cent of Singapore's local resident population (450,000 residents) - and build evidence on how genomic information can be used responsibly in healthcare at population scale, while continuing to support research into health and disease. "Phase III is not simply about sequencing more genomes. It is about ensuring that NPM Phase III can manage genomic data securely and responsibly, in ways that support both research and care. The Joint Innovation Centre gives us a practical way to develop the platforms we need, keep them current and ensure they continue to meet evolving needs in this fast developing field without compromising security or scientific quality," said Professor Patrick Tan, Executive Director of PRECISE. The JIC builds on work that PRECISE and Temus have undertaken together since 2024, providing a proven foundation for the next phase of the partnership. This includes plans to build a secure genomics data infrastructure that handles around 13.6 petabytes of genomic data - scaling to more than 60 petabytes, cutting data-processing timelines from weeks to days, and generating genome-wide association results for 100,000 genomes. The work spans data pipelines, research platforms, and visualisation solutions. Building on secure genomics infrastructure The JIC aims to place this work within a longer-term operating model. Scientists and engineers will work together to develop shared platforms for processing and analysing whole-genome data efficiently, sustainably and securely. The centre will also help ensure that these platforms can be maintained and improved as programme needs evolve, rather than rebuilt for each new project. The team will also establish structured processes and appropriate safeguards to assess and integrate emerging methodologies and technologies, including AI-enabled tools. "Precision health is a powerful example of why technology alone is not the solution. The science is advancing at a rapid pace, and AI is giving us increasingly powerful tools, but that requires trusted data, strong engineering, appropriate safeguards and people who know how to make all of those pieces work together," said Sng Ren Yeong, Chief Executive Officer of Temus. "We are honoured to deepen our partnership and support for PRECISE. Together, we can help turn scientific priorities into useful platforms scalably for researchers and practitioners, while building the talent and institutional capabilities needed to sustain that progress for Singapore over the long term." Developing talent and delivery capability Beyond enabling precision health and innovation, the JIC is expected to build specialist delivery capability development across Singapore's precision health ecosystem. In partnership with PRECISE, Temus plans to explore talent development pathways for specialist consultants and engineers in areas such as computational biology and bioinformatics specific to precision medicine and genomics. These specialists would work alongside research and technology teams to build practical expertise through live projects. For Temus, the JIC also represents a significant healthcare application of its AI Foundry, one of the priority sectors under Singapore's National AI Impact Programme. Launched in May 2026 at ATxSummit with support from Digital Industry Singapore, the AI Foundr y is hiring, developing and deploying 50 Singapore-based AI professionals in live enterprise projects, building production-grade AI assets, data pipelines, governance frameworks and human-in-the-loop systems for regulated and operationally complex environments. Hashtag: #Temus #PrecisionHealth #Genomics The issuer is solely responsible for the content of this announcement. About PRECISE. Precision Health Research, Singapore (PRECISE) leads the National Precision Medicine (NPM) programme, advancing genomics to improve health and grow Singapore's biomedical sector. Phase II sequenced 100,000 Singaporeans, while Phase III, in partnership with Singapore's three healthcare clusters, is evaluating how genomics can be integrated into clinical care responsibly. PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). NPM Phase II is supported by the National Research Foundation, Singapore under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734). For more information, visit About Temus. Temus helps public sector agencies and private enterprises transform how they work and serve citizens and customers with production-grade AI, cloud and application engineering, consulting and design, in line with Singapore's Smart Nation and National AI ambitions. Its work spans health, defence, financial services, education and government. Established by Temasek in 2021, Temus is about 600-strong and anchored in Singapore with a growing regional presence.

Philippines' first APAC services partner Thinking Machines receives funding from Singapore's Temus. Thinking Machines Data Science, a Manila-based AI and data startup and OpenAI's first official services partner in Asia Pacific, has received a strategic investment from Temus, a Singapore-based AI and digital transformation firm launched by Temasek in 2021. Temus said the collaboration can assist businesses throughout Southeast Asia in transitioning from AI experimentation to production deployment in a statement released on Thursday without providing financial details. Temus' enterprise transformation strengths in cloud and application engineering, consulting, and design can be combined with Thinking Machines' expertise in data platforms, AI deployment, and OpenAI-enabled services. Temus supports Singapore's Smart Nation and National AI Strategy priorities while collaborating with public and private sector organizations in the fields of healthcare, finance, education, and government. Founded by Stephanie Sy in 2015, Thinking Machines has taught over 10,000 people in AI, served over 110 clients, and put hundreds of AI systems into production in the financial services, retail, corporate, and public sectors. It has offices in Bangkok, Singapore, and Manila. Sy will remain CEO of Thinking Machines and take on the role of Managing Director of Applied AI and Data at Temus after the investment. According to Temus CEO Sng Ren Yeong, Thinking Machines offers the deep engineering, governance, and integration capabilities required to operate AI systems in real-world scenarios with limited data, complicated workflows, and regulatory restrictions. The executive stated that the investment can increase the use of AI.